Cobenfy

[@brocksprogramming]

Thank you so much for your honest information on this. I'm glad there are people that tell the other side of the story. I hadn't really thought of the duration of the study and what ramifications a short study could have.

[@SchizoShreds]

The EMERGENT-4 study, a 52-week, open-label extension trial, yielded promising results for KarXT (xanomeline-trospium) in treating schizophrenia. Here are some key findings: Symptom Improvement: Over 75% of participants achieved at least a 30% improvement in symptoms, with an average reduction of 33.3 points from baseline on the Positive and Negative Syndrome Scale (PANSS)1. Metabolic Profile: Most patients experienced stability or improvements in metabolic parameters, with a mean weight decrease of 2.6 kg over the year2. Safety and Tolerability: KarXT was generally well tolerated, with no significant changes in prolactin levels or clinically meaningful changes in movement disorder scale scores2. Long-Term Efficacy: The study confirmed the long-term efficacy of KarXT, showing continued improvements in schizophrenia symptoms over the 52 weeks3. These results suggest that KarXT could be a differentiated treatment option for people living with schizophrenia, offering a favorable safety and metabolic profile along with significant symptom improvement.

[@kimberlysmrek2929]

75% only saw 30% improvement? Thats a high number of people with low results. No?

[@enzoaurelius5606]

Thank you for keeping awarness

[@johnparedes285]

nice

[@sharmarustam]

You are wrong there was a 52 week long term trail done on it to prove its efficacy

[@patdeegan]

Yes, in a paper just presented at the Psych Congress in Boston at the beginning of November 2024

[@vegandolls]

it couldnt be worse then the antipsychotics already on the market... right?😅

[@RaySipes]

which can destroy your life permanently

[@johnparedes285]

nice